Epigenetic targets in the diagnosis and treatment of prostate cancer

AUTOR(ES)

Manoharan, Murugesan, Ramachandran, Kavitha, Soloway, Mark S., Singal, Rakesh

FONTE

International braz j urol

DATA DE PUBLICAÇÃO

2007-02

RESUMO

Prostate cancer (PC) is one of leading cause of cancer related deaths in men. Various aspects of cancer epigenetics are rapidly evolving and the role of 2 major epigenetic changes including DNA methylation and histone modifications in prostate cancer is being studied widely. The epigenetic changes are early event in the cancer development and are reversible. Novel epigenetic markers are being studied, which have the potential as sensitive diagnostic and prognostic marker. Variety of drugs targeting epigenetic changes are being studied, which can be effective individually or in combination with other conventional drugs in PC treatment. In this review, we discuss epigenetic changes associated with PC and their potential diagnostic and therapeutic applications including future areas of research.

Documentos Relacionados

• Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986–2005
• Diagnosis and treatment of prostate cancer: summary of NICE guidance
• Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
• THE EARLY DIAGNOSIS OF CANCER IN THE BLADDER, PROSTATE AND KIDNEY *
• Recommendations for prostate cancer diagnosis and treatment during COVID-19 outbreak were not followed in Brazil